SEARCH:   Advanced

Blood, 15 May 2007, Vol. 109, No. 10, pp. 4164-4167. Prepublished online as a Blood First Edition Paper on January 30, 2007; DOI 10.1182/blood-2006-09-045351. This Article Full Text Full Text (PDF) Supplemental Methods and Appendix All Versions of this Article: blood-2006-09-045351v1 109/10/4164    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Wetzler, M. Articles by Larson, R. A. Search for Related Content PubMed PubMed Citation Articles by Wetzler, M. Articles by Larson, R. A. Related Collections Neoplasia Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511 Meir Wetzler1, Ben L. Sanford2, Joanne Kurtzberg3, Divino DeOliveira3, Stanley R. Frankel4, Bayard L. Powell5, Jonathan E. Kolitz6, Clara D. Bloomfield7, and Richard A. Larson8 1 Leukemia Section, Roswell Park Cancer Institute, Buffalo, NY; 2 Cancer and Leukemia Group B (CALGB) Biostatistics, Duke University Medical Center, Durham, NC; 3 Duke University Medical Center, Durham, NC; 4 Marlene and Stewart Greenebaum Cancer Center, University of Maryland Cancer Center, Baltimore; 5 Wake Forest University School of Medicine, Winston-Salem, NC; 6 North Shore University Hospital, Manhasset, NY; 7 Ohio State University Comprehensive Cancer Center, Columbus; 8 University of Chicago, IL CALGB 9511 used pegaspargase (PEG-ASP) in lieu of the native enzyme. The aim was to compare differences in overall survival (OS) and disease-free survival (DFS) between patients who did and did not achieve asparagine depletion, defined by enzyme levels greater than 0.03 U/mL plasma for 14 consecutive days after at least 1 of 4 planned PEG-ASP administrations. Samples were available from 85 eligible patients. On univariate analyses, the 22 patients who did not achieve asparagine depletion had inferior OS (P = .002; hazard ratio [HR] = 2.37; 95% CI = 1.38-4.09) and DFS (P = .012; HR = 2.21; 95% CI = 1.19-4.13). After adjusting for age, performance status, leukocyte count, and karyotype in a proportional hazards model, both the OS and DFS HRs decreased to 1.8 (P = .056; 95% CI = 1.0-3.2 and P = .084; 95% CI = 0.9-3.6, respectively). We conclude that effective asparagine depletion with PEG-ASP is feasible as part of an intensive multiagent therapeutic regimen in adult acute lymphoblastic leukemia and appears associated with improved outcomes. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. M. Rowe and A. H. Goldstone How I treat acute lymphocytic leukemia in adults Blood, October 1, 2007; 110(7): 2268 - 2275. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020